recoveryCellular

BPC-157

BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid pentadecapeptide derived from a protein sequence found in human gastric juice. The full name is Body Protection Compound, reflecting its discovery in a broader search for cytoprotective agents from the gut. It was first isolated and characterized by researchers at the University of Zagreb in the 1990s and has since been studied extensively in animal models.

half-life
~4 hours
route
subcutaneous or oral
cadence
once or twice daily
storage
refrigerated · 28-day max
typical dose
250–500 mcg / day
cycle
4–12 weeks
Dose calculatorlive
U-100
Concentration
2.50mg/mL
Injection vol.
0.100mL
Syringe cap.
100units
Draw to10units
02040608010010 units
vial × bac → conc → vol → unitsverified math · open source
How it works

What is BPC-157?

BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid pentadecapeptide derived from a protein sequence found in human gastric juice. The full name is Body Protection Compound, reflecting its discovery in a broader search for cytoprotective agents from the gut. It was first isolated and characterized by researchers at the University of Zagreb in the 1990s and has since been studied extensively in animal models.

In animal research, BPC-157 has demonstrated consistent regenerative effects across multiple tissue types. Studies in rodents show accelerated healing of tendons (including the Achilles and patellar tendons), ligaments, muscle tissue, bone, and gut mucosa. The proposed mechanisms include upregulation of growth hormone receptors in fibroblasts, modulation of the nitric oxide (NO) system for enhanced angiogenesis (new blood vessel growth), and reduction of inflammatory cytokines. BPC-157 appears to work systemically even when injected subcutaneously at a distant site, not just near the injury.

For gut-related applications, BPC-157 has shown particularly strong results in animal models of inflammatory bowel disease, stomach ulcers, and intestinal fistulas. Unlike many peptides, BPC-157 survives gastric acid reasonably well due to its stability, making oral administration a viable route for GI-specific conditions. For systemic or musculoskeletal use, subcutaneous injection is the standard route.

Reconstituting BPC-157 follows the same procedure as other research peptides: add bacteriostatic water slowly along the vial wall, gently roll to mix (never shake), and refrigerate. A common preparation is 5 mg vial with 2 mL BAC water, giving 2,500 mcg/mL. At a 250 mcg dose, that is 0.1 mL or 10 units on a U-100 syringe, precise and measurable. Reconstituted BPC-157 is stable for approximately 28 days at 2–8°C.

Important context: there are no completed human clinical trials of BPC-157. All efficacy data comes from animal studies (primarily rats). BPC-157 is not FDA-approved for any indication and is sold strictly for research purposes. The animal study results are promising enough that it has become one of the most widely self-administered research peptides, but the absence of human trial data means all dosing is extrapolated from animal models adjusted for body weight.

Common questions

BPC-157 Frequently Asked Questions

250–500 mcg per day is the most commonly used range in research protocols, derived from rat studies scaled to human body weight. Some split this into two injections (morning and evening). There is no established clinical dose, all human use is extrapolated from animal data.
Sources

Research & References

BPC-157: a review of its regenerative properties in tendon and ligament healingPubMed · Journal of Physiology and Pharmacology 2018Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10)PubMed · Curr Pharm Des 2011BPC-157 and angiogenesis, nitric oxide mechanismPubMed · Inflammopharmacology 2019
Also calculate

Related Peptide Calculators